Abstract:Abstract Background Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States with no effective treatment. The current diagnostic method, spirometry, does not accurately reflect the severity of COPD disease status. Therefore, there is a pressing unmet medical need to develop noninvasive methods and reliable biomarkers to detect early stages of COPD. Lipids are the fundamental components of cell membranes, and dysregulation of lipids was proven to be associated with COPD. Lipidomics is a comprehensive approach to all the pathways and networks of cellular lipids in biological systems. It is widely used for disease diagnosis, biomarker identification, and pathology disorders detection relating to lipid metabolism. Methods In the current study, a total of 25 serum samples were collected from 5 normal control subjects and 20 patients with different stages of COPD according to the global initiative for chronic obstructive lung disease (GOLD) (GOLD stages I ~ IV, 5 patients per group). After metabolite extraction, lipidomic analysis was performed using electrospray ionization mass spectrometry (ESI-MS) to detect the serum lipid species. Later, the comparisons of individual lipids were performed between controls and patients with COPD. Orthogonal projections to latent structures discriminant analysis (OPLS-DA) and receiver operating characteristic (ROC) analysis were utilized to test the potential biomarkers. Finally, correlations between the validated lipidomic biomarkers and disease stages, age, FEV1% pack years and BMI were evaluated. Results Our results indicate that a panel of 50 lipid metabolites including phospholipids, sphingolipids, glycerolipids, and cholesterol esters can be used to differentiate the presence of COPD. Among them, 10 individual lipid species showed significance ( p < 0.05) with a two-fold change. In addition, lipid ratios between every two lipid species were also evaluated as potential biomarkers. Further multivariate data analysis and receiver operating characteristic (ROC: 0.83 ~ 0.99) analysis suggest that four lipid species (AUC:0.86 ~ 0.95) and ten lipid ratios could be potential biomarkers for COPD (AUC:0.94 ~ 1) with higher sensitivity and specificity. Further correlation analyses indicate these potential biomarkers were not affected age, BMI, stages and FEV1%, but were associated with smoking pack years. Conclusion Using lipidomics and statistical methods, we identified unique lipid signatures as potential biomarkers for diagnosis of COPD. Further validation studies of these potential biomarkers with large population may elucidate their roles in the development of COPD.

An integrated metabo-lipidomics profile of induced sputum for the identification of novel biomarkers in the differential diagnosis of asthma and COPD

Stratification of asthma by lipidomic profiling of induced sputum supernatant

Sputum Metabolomic Profiling Reveals Metabolic Pathways and Signatures Associated with Inflammatory Phenotypes in Patients with Asthma

Proteomic Signatures in Serum and Induced Sputum

Integrative genetic and metabolite profiling analysis suggests altered phosphatidylcholine metabolism in asthma.

Breath and Sputum Analyses in Asthmatic Patients: An Overview

Immunological profiling and development of a sensing device for detection of IL-13 in COPD and asthma

Biomarkers obtained by non-invasive methods in patients with COPD: where do we stand, what do we expect?

Identification of lipid biomarker from serum in patients with chronic obstructive pulmonary disease

Urinary Metabolomic Profiling Reveals Biological Pathways and Predictive Signatures Associated with Childhood Asthma

Cytokine biomarkers of exacerbations in sputum from Chronic Obstructive Pulmonary Disease patients: a prospective cohort study

A Comparison of Serum and Sputum Inflammatory Mediator Profiles in Patients with Asthma and COPD.

Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD.

Eicosanoids metabolized through LOX distinguish asthma-COPD overlap from COPD by metabolomics study

Metabolomic Profiling Differences among Asthma, COPD and Healthy Controls: a LC-MS-based Metabolomics Analysis

A cross-omics integrative study of metabolic signatures of chronic obstructive pulmonary disease

NMR-Based Metabolomics for the Assessment of Inhaled Pharmacotherapy in Chronic Obstructive Pulmonary Disease Patients

Design of a multi-center immunophenotyping analysis of peripheral blood, sputum and bronchoalveolar lavage fluid in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)

Metabolomic Profiling Differences among Asthma, COPD, and Healthy Subjects: A LC-MS-based Metabolomic Analysis.

Selection of Disease-Specific Biomarkers by Integrating Inflammatory Mediators with Clinical Informatics in Patients with Aecopd: A Preliminary Study

Induced Sputum Metabolomic Profiles and Oxidative Stress Are Associated with Chronic Obstructive Pulmonary Disease (COPD) Severity: Potential Use for Predictive, Preventive, and Personalized Medicine.